Security
Lyell Immunopharma, Inc. Common Stock · LYEL
LYELNASDAQCommon stockCurrentCIK 1806952Updated Nov 6, 2026
LYEL price & chart
Loading TradingView…
NASDAQ:LYEL on TradingView ↗About the company
Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s lead product candidate, LYL314, is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to the approved CD19-targeted CAR T-cell therapies for the treatment of large B-cell lymphoma. The PiNACLE trial is an ongoing single-arm pivotal trial evaluating LYL314 in patients with large B-cell lymphoma that has relapsed and/or been refractory to two or more lines of prior therapy. The Lyell LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.l…
In the news
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer ↗
Recent filings
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Unregistered Sales of Equity Securities
Items 3.02
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 407,965,000Source | 619,215,000Source | 311,153,000Source | 385,453,000Source | 654,142,000Source | 350,626,000Source | 429,798,000Source | 694,220,000Source | 340,052,000Source | 490,859,000Source | 750,029,000Source | 937,561,000Source |
| Property, Plant and Equipment, NetUSD | 36,722,000Source | 88,047,000Source | 30,507,000Source | 39,115,000Source | 93,096,000Source | 32,720,000Source | 44,195,000Source | 97,836,000Source | 34,771,000Source | 48,200,000Source | 102,654,000Source | 123,023,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 123,575,000Source | 100,299,000Source | 72,985,000Source | 98,804,000Source | 133,424,000Source | 90,770,000Source | 120,328,000Source | 125,650,000Source | 60,181,000Source | 105,597,000Source | 145,647,000Source | 123,554,000Source |
| Assets, CurrentUSD | 328,201,000Source | 450,045,000Source | 213,541,000Source | 282,214,000Source | 499,824,000Source | 267,304,000Source | 309,178,000Source | 534,165,000Source | 260,939,000Source | 379,594,000Source | 554,686,000Source | 651,295,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,577,000Source | 9,498,000Source | 9,439,000Source | 5,424,000Source | 8,705,000Source | 13,281,000Source | 8,001,000Source | 7,865,000Source | 13,719,000Source | 9,067,000Source | 8,463,000Source | 11,143,000Source |
| Operating Lease, Right-of-Use AssetUSD | 19,912,000Source | 36,662,000Source | 16,781,000Source | 20,951,000Source | 37,696,000Source | 17,828,000Source | 23,570,000Source | 38,695,000Source | 18,871,000Source | 24,739,000Source | 39,663,000Source | 43,242,000Source |
| Other Assets, NoncurrentUSD | 2,545,000Source | 5,061,000Source | 5,841,000Source | 2,530,000Source | 4,239,000Source | 5,234,000Source | 3,218,000Source | 4,238,000Source | 4,886,000Source | 4,622,000Source | 4,235,000Source | 4,680,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 78,844,000Source | 88,518,000Source | 77,338,000Source | 86,530,000Source | 87,641,000Source | 76,961,000Source | 93,277,000Source | 91,063,000Source | 91,850,000Source | 108,035,000Source | 95,077,000Source | 104,309,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,000Source | 26,000Source | 2,000Source | 1,000Source | 26,000Source | 2,000Source | 30,000Source | 25,000Source | 2,000Source | 29,000Source | 25,000Source | 25,000Source |
| Additional Paid in CapitalUSD | 1,807,749,000Source | 1,683,082,000Source | 1,922,433,000Source | 1,738,850,000Source | 1,675,460,000Source | 1,917,379,000Source | 1,733,634,000Source | 1,666,315,000Source | 1,867,512,000Source | 1,727,610,000Source | 1,657,133,000Source | 1,608,306,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,478,831,000Source | -1,153,171,000Source | -1,688,462,000Source | -1,439,985,000Source | -1,108,588,000Source | -1,643,707,000Source | -1,397,301,000Source | -1,062,779,000Source | -1,619,554,000Source | -1,345,106,000Source | -1,002,112,000Source | -767,480,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 201,000Source | 760,000Source | -158,000Source | 57,000Source | -397,000Source | -9,000Source | 158,000Source | -404,000Source | 242,000Source | 291,000Source | -94,000Source | -7,599,000Source |
| Stockholders' Equity Attributable to ParentUSD | 329,121,000Source | 530,697,000Source | 233,815,000Source | 298,923,000Source | 566,501,000Source | 273,665,000Source | 336,521,000Source | 603,157,000Source | 248,202,000Source | 382,824,000Source | 654,952,000Source | 833,252,000Source |
| Liabilities and EquityUSD | 407,965,000Source | 619,215,000Source | 311,153,000Source | 385,453,000Source | 654,142,000Source | 350,626,000Source | 429,798,000Source | 694,220,000Source | 340,052,000Source | 490,859,000Source | 750,029,000Source | 937,561,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 31,878,000Source | 33,512,000Source | 39,867,000Source | 36,903,000Source | 30,879,000Source | 36,947,000Source | 41,285,000Source | 32,353,000Source | 49,412,000Source | 53,788,000Source | 34,519,000Source | 37,028,000Source |
| Operating Lease, Liability, CurrentUSD | 8,788,000Source | 7,134,000Source | 9,664,000Source | 8,510,000Source | 6,898,000Source | 9,364,000Source | 8,238,000Source | 6,667,000Source | 9,073,000Source | 7,974,000Source | 6,273,000Source | 4,534,000Source |
| Accounts Payable, CurrentUSD | 2,568,000Source | 3,596,000Source | 3,879,000Source | 3,379,000Source | 4,199,000Source | 5,468,000Source | 3,728,000Source | 4,895,000Source | 2,893,000Source | 5,366,000Source | 4,817,000Source | 3,917,000Source |
| Operating Lease, Liability, NoncurrentUSD | 44,285,000Source | 51,441,000Source | 36,934,000Source | 46,597,000Source | 53,323,000Source | 39,487,000Source | 48,851,000Source | 55,159,000Source | 41,921,000Source | 50,994,000Source | 56,894,000Source | 63,168,000Source |
| Other Liabilities, NoncurrentUSD | 2,681,000Source | 3,565,000Source | 537,000Source | 3,030,000Source | 3,439,000Source | 527,000Source | 3,141,000Source | 3,551,000Source | 517,000Source | 3,253,000Source | 3,664,000Source | 4,113,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 2,332,000Source | 3,441,000Source | 11,539,000Source | 19,631,000Source | 20,250,000Source | 18,020,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,295,000Source | 6,024,000Source | 41,829,000Source | 33,144,000Source | 47,084,000Source | 81,924,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,383,000Source | -1,654,000Source | -2,339,000Source | -3,234,000Source | 1,464,000Source | 667,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -38,510,000Source | -54,738,000Source | -150,024,000Source | -162,394,000Source | -163,694,000Source | -169,555,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 17,378,000Source | 69,466,000Source | 54,097,000Source | 122,424,000Source | 184,048,000Source | -11,540,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 89,000Source | 246,000Source | 780,000Source | 464,000Source | 2,686,000Source | 24,276,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 0Source | — | 1,000Source | 76,000Source | 457,000Source | 461,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 51,722,000Source | 1,000Source | 50,406,000Source | 1,326,000Source | 1,743,000Source | 10,635,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 30,590,000Source | 14,729,000Source | -45,521,000Source | -38,644,000Source | 22,097,000Source | -170,460,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 125,160,000Source | 100,587,000Source | 74,572,000Source | 100,388,000Source | 92,356,000Source | 122,016,000Source | 61,766,000Source | 107,287,000Source | 145,931,000Source | 123,834,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,232,000Source | 7,622,000Source | 4,532,000Source | 5,004,000Source | 4,295,000Source | 6,024,000Source | 41,829,000Source | 33,144,000Source | 47,084,000Source | 81,924,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | — | — | — | 5,525,000Source | — | 6,389,000Source | — | 7,600,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 10,400,000Source | 19,400,000Source | 20,200,000Source | 18,000,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | 0Source | -26,000Source | -30,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | 0Source | -1,291,000Source | -3,344,000Source | -1,341,000Source | -1,509,000Source | -103,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 10,687,000Source | 11,769,000Source | 9,576,000Source | 9,786,000Source | 9,555,000Source | 14,046,000Source | 45,135,000Source | 52,041,000Source | 66,983,000Source | 117,307,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -38,846,000Source | -44,583,000Source | -44,755,000Source | -42,684,000Source | -24,153,000Source | -52,195,000Source | -274,448,000Source | -342,994,000Source | -234,632,000Source | -183,118,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -183,118,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,593,000Source | 5,922,000Source | 2,582,000Source | 4,456,000Source | 20,108,000Source | 5,172,000Source | -5,044,000Source | 15,761,000Source | 12,376,000Source | 3,940,000Source |
| Operating ExpensesUSD | — | — | 37,268,000Source | 50,539,000Source | 47,341,000Source | 47,148,000Source | 44,263,000Source | 57,374,000Source | 269,440,000Source | 358,816,000Source | 247,138,000Source | 271,741,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -4,859,000Source | -43,000Source | 398,000Source | 1,180,000Source | 17,914,000Source | 1,310,000Source | -18,124,000Source | 4,694,000Source | 1,846,000Source | 1,887,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 1,591,000Source | 730,000Source | 1,759,000Source | -1,062,000Source | 1,896,000Source | 119,000Source | 2,145,000Source | 3,309,000Source | 2,790,000Source | 4,754,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 50,000,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 26,000Source | 0Source | 42,000Source | 154,000Source | 306,000Source | 9,577,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 15,000Source | 34,000Source | 4,000Source | 8,000Source | 2,000Source | 7,000Source | 36,000Source | 61,000Source | 130,000Source | 84,683,000Source |
| Operating Income (Loss)USD | — | — | -37,253,000Source | -50,505,000Source | -47,337,000Source | -47,140,000Source | -44,261,000Source | -57,367,000Source | -269,404,000Source | -358,755,000Source | -247,008,000Source | -187,058,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -4,859,000Source | -43,000Source | 398,000Source | 1,180,000Source | 17,914,000Source | 1,310,000Source | -18,124,000Source | 4,694,000Source | 1,846,000Source | 1,887,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -38,846,000Source | -44,583,000Source | -44,755,000Source | -42,684,000Source | -24,153,000Source | -52,195,000Source | -274,448,000Source | -342,994,000Source | -234,632,000Source | -183,118,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.13Source | -3.48Source | -1.92Source | -2.89Source | -1.1Source | -3.54Source | -16.06Source | -1.31Source | -0.93Source | -0.74Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.13Source | -3.48Source | -1.92Source | -2.89Source | -1.1Source | -3.54Source | -16.06Source | -1.31Source | -0.93Source | -0.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 18,268,000Source | 12,815,000Source | 23,364,000Source | 14,793,000Source | 21,876,000Source | 14,755,000Source | 17,093,000Source | 261,480,000Source | 250,983,000Source | 247,080,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 18,268,000Source | 12,815,000Source | 23,364,000Source | 14,793,000Source | 21,876,000Source | 14,755,000Source | 17,093,000Source | 261,480,000Source | 250,983,000Source | 247,080,000Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 10,687,000Source | 11,769,000Source | 9,576,000Source | 9,786,000Source | 9,555,000Source | 14,046,000Source | 45,135,000Source | 52,041,000Source | 66,983,000Source | 117,307,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 3,266,000Source | 5,965,000Source | 2,184,000Source | 3,276,000Source | 2,194,000Source | 3,862,000Source | 13,080,000Source | 24,068,000Source | 23,453,000Source | 7,053,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -183,118,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,593,000Source | 5,922,000Source | 2,582,000Source | 4,456,000Source | 20,108,000Source | 5,172,000Source | -5,044,000Source | 15,761,000Source | 12,376,000Source | 3,940,000Source |
| Operating ExpensesUSD | — | — | 37,268,000Source | 50,539,000Source | 47,341,000Source | 47,148,000Source | 44,263,000Source | 57,374,000Source | 269,440,000Source | 358,816,000Source | 247,138,000Source | 271,741,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 1,591,000Source | 730,000Source | 1,759,000Source | -1,062,000Source | 1,896,000Source | 119,000Source | 2,145,000Source | 3,309,000Source | 2,790,000Source | 4,754,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | — | 28,172,000Source | 39,500,000Source | 39,524,000Source | 34,857,000Source | 36,604,000Source | 43,447,000Source | — | — | 182,945,000Source | 159,188,000Source |
Offerings
Registration 333-297433
Registration 333-294884
Filing attachments
d278670dex991.htm · 8-K · 2026-09-10
EX-99.1 2 d278670dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer Technology transfer to LyFE Manufacturing CenterTM completed following FDA review of improved manufacturing process and updated analytical methods Dosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optim…
Read attachment ↗ex-107_lyellimmunopharmain.htm · 10-K · 2026-03-12
Exhibit 10.7 Lyell Immunopharma, Inc. Non-Employee Director Compensation Policy Adopted by the Board of Directors: November 11, 2019 Last Amended and Restated: April 24, 2024, to be effective June 14, 2024 Effective Date: June 14, 2024 Each member of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) who is a non-employee director of the Company (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Comp…
Read attachment ↗d57756dex991.htm · 8-K · 2025-11-10
EX-99.1 2 d57756dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trial LYL273 …
Read attachment ↗d24368dex41.htm · 8-K · 2025-07-25
EX-4.1 2 d24368dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN…
Read attachment ↗d24368dex991.htm · 8-K · 2025-07-25
EX-99.1 4 d24368dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Lyell Immunopharma Announces up to $100 Million Equity Private Placement SOUTH SAN FRANCISCO, Calif., July 25, 2025 - Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up…
Read attachment ↗